COVID 19 and the Systematic Use of Aspirin in Diabetics During Hospitalization: A Retrospective Study

Background and Aims Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, has infected more than 153 million people and led to the death of 3.3 million others. It is estimated that people with cardiovascular risk factors are more prone for mortality and intubation. especially obesity, and his is especially true in Saudi Arabia and the region of Hail, where morbid obesity (BMI >30) is at 33.6% of the population. Our aim is to establish an epidemiological link for our population between aspirin use, diabetes, obesity and percentage of intubated patients as we measured mortalities and readmissions in 30 days. Methods A retrospective cohort study of 753 patients admitted as positive COVID 19 patients, from April 1, 2020 to July 31, 2020, covering a period of 4 months. We then categorised the patient in cohorts according to the use of aspirin or not, existence of diabetes or not, and categorised them according to their BMI index. We then correlated using statistical tool analysis - SPSS statistics tool - intubation, mortality, readmittance in 30 days in these groups of patients Results Around 40% of our cases were diabetic. 18% of the diabetic cases intubated, instead of 7% of non DM cases. Mortalities were higher in the diabetic group as percentage (14% to 7%), and readmissions and lower in the aspirin group. Significant correlation between BMI and days of ICU stay Conclusions There is significant morbidity in DM patients with COVID 19, especially morbid obese. Aspirin has statistically significant effects